Ricevi le ultime notizie sulle azioni Editas Medicine con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di EDIT

Ultime notizie per

Editas Medicine

Editas Medicine Inc

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Candel Therapeutics

Crescent Biopharma

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

ETHZilla

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Foghorn Therapeutics

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Palisade Bio

Puma Biotechnology

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Pyxis Oncology

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Exagen

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Editas Medicine (EDIT) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Commerci governativi

Rapporto azionario

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Comments

Editas Medicine Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO